Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.
about
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaAdherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.Productivity and deadweight losses due to relapses of schizophrenia in JapanA long-acting integrase inhibitor protects female macaques from repeated high-dose intravaginal SHIV challenge.New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents.Clinical benefits and impact of early use of long-acting injectable antipsychotics for schizophrenia.Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Adherence, persistence, and inpatient utilization among adult schizophrenia patients using once-monthly versus twice-monthly long-acting atypical antipsychotics.Dual-stimuli responsive injectable microgel/solid drug nanoparticle nanocomposites for release of poorly soluble drugs.All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics.Comparison of the G and V methods for ventrogluteal site identification: Muscle and subcutaneous fat thicknesses and considerations for successful intramuscular injection.
P2860
Q24597701-3CF4CBE3-05A5-45E3-B7DA-7779F0C9012FQ30937746-E98E8B5C-262B-4A05-8003-2B8D44F68A60Q33650097-3963E006-30EB-4BA7-8A76-68517EEFD540Q33713733-7F398E32-DE56-4D7B-BE60-FD79B3CFA048Q35667426-697C85EC-F7D3-48E3-920E-F9B505B73F4CQ38170326-7FE526AE-9A98-4F6E-ADB2-A2B0FD18E247Q38592404-FF349652-D5C1-40F2-870A-1E9B40926AA3Q40512185-5FFA3F55-3193-43C6-91F6-A1FB0A35D0D4Q47998008-13D299FD-AE93-48BC-921A-C500A03929D3Q48337638-497DBF6E-EEF1-4661-8E73-F58E8078BE5BQ50066712-20916BAD-A46D-4469-B910-39627D525936Q53137694-EADEFC3F-C000-4542-8845-5BD438F8256A
P2860
Long-acting antipsychotic drugs for the treatment of schizophrenia: use in daily practice from naturalistic observations.
description
2012 nî lūn-bûn
@nan
2012 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Long-acting antipsychotic drug ...... rom naturalistic observations.
@ast
Long-acting antipsychotic drug ...... rom naturalistic observations.
@en
Long-acting antipsychotic drug ...... rom naturalistic observations.
@nl
type
label
Long-acting antipsychotic drug ...... rom naturalistic observations.
@ast
Long-acting antipsychotic drug ...... rom naturalistic observations.
@en
Long-acting antipsychotic drug ...... rom naturalistic observations.
@nl
prefLabel
Long-acting antipsychotic drug ...... rom naturalistic observations.
@ast
Long-acting antipsychotic drug ...... rom naturalistic observations.
@en
Long-acting antipsychotic drug ...... rom naturalistic observations.
@nl
P2860
P356
P1433
P1476
Long-acting antipsychotic drug ...... rom naturalistic observations.
@en
P2093
Andrea Rossi
Sonia Frediani
P2860
P2888
P356
10.1186/1471-244X-12-122
P577
2012-08-21T00:00:00Z
P6179
1031620572